S

Stylus Medicine

In vivo genome editing for CAR-T

Research Associate - Molecular & Cellular Immunology

Translational Research & Bench BiologyConfirmed live in the last 24 hours
Full-timeCambridge, MA, USA$85k - $95kIn-person

About the Job

Requirements

  • A bachelor's degree in Biology, Bioengineering, Immunology, or a related field is required.
  • Hands-on molecular biology experience, including polymerase chain reaction, cloning, bacterial transformations, minipreps, maxipreps, and in vitro transcription is required.
  • Hands-on mammalian cell culture expertise, including culturing tumor cell lines and primary T cells or peripheral blood mononuclear cells, co-culture experiments, flow cytometry, and genomic DNA extraction is required.
  • Ability to execute, interpret, and troubleshoot experiments independently and collaboratively is required.
  • Experience maintaining meticulous records, including an organized lab notebook, lab inventory, and experimental results, is required.
  • Ability to convey technical information and collaborate in a fast-paced, rapidly developing environment is required.
  • Enthusiasm and curiosity to learn and apply new laboratory techniques across a variety of sub-disciplines is required.

Responsibilities

  • Perform in vitro T cell experiments to evaluate the efficiency of recombinase-based engineering strategies and characterize the functional ability of resulting CAR-T cells.
  • Perform cloning and prepare nucleic acid materials and/or lipid nanoparticles to support cell culture experiments.
  • Analyze and interpret data and produce data reports to inform project direction.
  • Communicate findings to internal teams.
  • Maintain detailed and accurate laboratory records in compliance with data integrity and documentation standards.

Desired Qualifications

  • Familiarity with producing targeted lipid nanoparticles and/or working with CAR-T cells is preferred.

About the Company

Stylus Medicine

In vivo genome editing for CAR-T

Stylus Medicine develops in vivo genetic medicines by combining engineered, therapeutic-grade recombinases with non-viral lipid nanoparticle (LNP) delivery. This platform enables sequence-specific genome integration to insert large genetic payloads directly inside a patient’s body, bypassing the complex steps of ex vivo cell modification. The initial focus is in oncology, delivering a recombinase and a CAR-encoding DNA payload to a patient’s T cells via LNP infusion, effectively turning the patient’s body into an in vivo CAR-T cell factory. The modular system can adapt CAR constructs to target different cancer antigens and holds potential for autoimmune and other genetic diseases beyond oncology. The company positions itself as an off-the-shelf, scalable genetic therapy approach that streamlines treatment workflows and broadens patient access by avoiding traditional ex vivo manufacturing.

Company size
11-50
Company stage
Series A
Total funding
$85M
Headquarters
Cambridge, MA
Founded
2022

Recently Posted Jobs

Explore more opportunities at Stylus Medicine

See more jobs